drugset / Trial / NCT00570531
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether bevacizumab can improve the outcome of treatment for patients with esophageal cancer whose disease is confined to the esophagus or the closely surrounding lymph nodes.
Timeline
- Start
- 2007-06
- Primary completion
- 2010-10
- Completion
- 2013-06
Outcome
Outcome not reported
Stopped (Enrollment): “The study was unable the accrue the required number of patients within a reasonable time.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Cisplatin | Other / unclassified | 30 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 45 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 200 mg/m2 | Intravenous |